Clinical Trials · NCT05144984
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 500
- Start date
- Nov 2021
- Locations
- 129 sites, 9 countries
- Primary endpoint
- Change From Baseline in Glycosylated Haemoglobin (HbA1c)